Article

Maintenance Lenalidomide Safe, Should Be Continued in Patients With Myeloma Who Contract COVID-19

Author(s):

Maintenance treatment with lenalidomide was found to be a safe treatment for patients with multiple myeloma who are diagnosed with COVID-19, supporting use of the immunomodulatory drug in this patient population.

Multiple myeloma

Multiple myeloma

Maintenance treatment with lenalidomide (Revlimid) was found to be a safe treatment for patients with multiple myeloma who are diagnosed with COVID-19, supporting use of the immunomodulatory drug (IMiD) in this patient population, according to single-center findings presented during the 2nd European Myeloma Network Meeting.

Data showed that the infection mortality rate was 23.8% in patients who were COVID-19 positive and on maintenance lenalidomide compared with 33.3% for those who had COVID-19 and not on lenalidomide. The recovery rates in both arms were 76.2% and 66.7%, respectively.

“Although cytopenias and immunoparesis may develop during continuous maintenance, lenalidomide seems to be safe and has effects in favor of less severe COVID-19 forms and also similar mortality among multiple myeloma patients,” said Ekin Kircali, MD, in the Department of Hematology at Ankara University School of Medicine, in Ankara, Turkey, in a virtual presentation of the data. “Based on our experience, we do not recommend discontinuation during this pandemic.”

Lenalidomide maintenance following consolidation therapy with high-dose melphalan is a common approach known to prolong progression-free survival in patients with myeloma, Kircali noted in her presentation. Lenalidomide may also induce neutropenia and lymphopenia, which in turn exposes patients to infections, including COVID-19.

However, small case series and other reports have suggested that IMiDs could protect patients from severe cases of COVID-19.

In the study presented during the meeting, investigators evaluated 60 patients with multiple myeloma between March 2020 and December 2020 and compared outcomes of those who received continuous lenalidomide maintenance (n = 42) vs no lenalidomide (n = 18).

Patient demographics were broken down into 3 groups: those who were COVID-19 positive and receiving lenalidomide (n = 21), COVID-19 negative and on lenalidomide (n = 21), and those who were COVID-19 positive and not on lenalidomide.

In the COVID-19–positive/lenalidomide group, the median age was 61 years (range, 57-70), and 10 patients were female. The number of lenalidomide cycles was 16 (range, 9-99), and 14 patients had a very good partial response (VGPR) or better to therapy; the neutrophil counts and lymphocyte counts were 1.43 (range, 0.74-9.2) and 0.97 (range, 0.01-2.84), respectively. IgG, IgA, and IgM levels were 7.94 mg/dL (range, 3.2-19.1), 0.69 mg/dL (range, 0.1-3.5), and 0.31 g/L (range, 0.1-0.7), respectively.

Also, in this arm, patients had either non-severe COVID-19 (n = 15) or severe COVID-19 (n = 6), and 5 patients died. The infection fatality rate was 23.8% and the recovery rate was 76.2%.

In the COVID-19–negative/lenalidomide group, the median age was 63 years (range, 58-71), and 11 patients were female. Sixty-one cycles (range, 10-90) of lenalidomide were given, and 18 patients had a VGPR or better to therapy. The neutrophil count was 1.65 (range, 0.77-4.24), and the lymphocyte count was 1.40 (range, 0.31-2.72). The IgG, IgA, and IgM levels were 9.46 mg/dL (range, 2.8-32.7), 1.73 mg/dL (range, 0.0-206), and 0.24 g/L (range, 0.1-0.9), respectively.

Within this group, 1 patient had died; the infection fatality rate was 4.8% and the recovery rate was not applicable as no patients here had COVID-19.

Finally, in the COVID-19–positive group without lenalidomide, the median age is 66 years (range, 46-79) and 12 patients were female. The number of lenalidomide cycles was not available, and 8 patients had a VGPR or better to therapy. The neutrophil count and lymphocyte count were 3.21 (range, 0.45-67.48) and 1.03 (range, 0.03-3.81). The IgG, IgA, and IgM levels were 10.25 mg/dL (range, 2.6-113), 0.41 mg/dL (range, 0.0-2.2), and 0.26 g/dL (0.0-1.3), respectively.

In this arm, 11 patients had non-severe COVID-19 and 7 patients had a severe case of the virus. Six patients died; the infection fatality rate was 33.3% and the recovery rate was 66.7%.

Reference

  1. Kircali, E, Seval GC, Toprak SK, et al. Outcome of COVID-19 infection occurring during lenalidomide maintenance. Presented at: 2nd European Myeloma Network Meeting; March 3-6, 2021; virtual. Abstract P34.
Related Videos
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique adverse effects, such as cytokine release syndrome and infection risks.
Jill Corre, PharmD, PhD
Jill Corre, PharmD, PhD